Trial Profile
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2020
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Vitamin K antagonists
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms RE-COVERY DVT/PE
- Sponsors Boehringer Ingelheim
- 20 Apr 2020 Results (n=6095) published in the American Journal of Medicine
- 18 Apr 2019 Status changed from active, no longer recruiting to completed.
- 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.